Novartis Sales Rise 4% as U.S. Patent or Exclusivity Expirations Are Estimated for 2031
Photo: TokenPost
Novartis’ net sales rose 4% in the third quarter of 2026 as growth from Kisqali and Kesimpta helped offset a 38% drop in Entresto amid generic competition. The Swiss drugmaker posted $14.522 billion in net sales. Worldwide sales of Entresto fell 38% to $1.165 billion, while Kisqali rose 37% to $1.821 billion and Kesimpta climbed 21% to $1.484 billion. Generic competition was the main factor in Entresto’s decline. Volume added 14 percentage points to sales growth, while generic competition subtracted nine points and pricing one point. The estimated U.S.
Source: TokenPost
